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Abstract 
 
Purpose: A number of parameters recorded during dobutamine stress echocardiography (DSE) 
are associated with worse outcome. However, the relative importance of baseline mitral 
regurgitation (MR) is unknown. The aim of this study was to assess the prevalence and 
associated implications of functional MR with long-term mortality in a large cohort of patients 
referred for DSE.  
 
Methods: 6745 patients (mean age 64.9±12.2 years) were studied. Demographic, baseline and 
peak DSE data were collected. All-cause mortality was retrospectively analyzed. DSE was 
successfully completed in all patients with no adverse outcomes. 
 
Results: MR was present in 1019 (15.1%) patients. During a mean follow up of 5.1±1.8 years, 
1642 (24.3%) patients died and MR was significantly associated with increased all-cause 
mortality (p<0.001). With Kaplan-Meier analysis, survival was significantly worse for patients 
with moderate and severe MR (p<0.001). With multivariate Cox regression analysis, moderate 
and severe MR (HR 2.78; 95% CI 2.17 - 3.57; and HR 3.62; 95% CI 2.89 - 4.53, respectively) 
were independently associated with all-cause mortality. The addition of MR to C statistic models 
significantly improved discrimination.  
 
Conclusions: MR is associated with all-cause mortality and adds incremental prognostic 
information among patients referred for DSE. The presence of MR should be taken into account 
when evaluating the prognostic significance of DSE results.  
 3 
Introduction 
 
Mitral regurgitation (MR) is the most common valvular heart disease and is often clinically 
silent, with prevalence increasing with age. It is estimated that 5-million of the US population 
will be affected by moderate or severe MR by 2030.[1] For patients with rheumatic and 
degenerative mitral valve disease the only definitive treatment is mitral valve repair or 
replacement. MR is an important long-term predictor of adverse outcome in patients with 
ischemic heart disease. After acute myocardial infraction,[2] coronary artery bypass graft 
surgery,[3] and percutaneous coronary intervention [4] outcome is related to the presence and 
severity of residual MR. For patients with stable coronary artery disease, MR is also associated 
with outcome.[5] 
 
Dobutamine stress echocardiography (DSE) is a widely accepted non-invasive test for the 
diagnosis, risk stratification and prognosis of coronary artery disease.[6] Several parameters have 
been shown to predict prognosis, such as, resting left ventricular (LV) systolic function, scar 
burden and the presence and extent of myocardial ischemia.[7,8] Functional MR determined 
using Doppler echocardiography is an independent predictor of cardiac mortality [9]. However, 
the relative prognostic importance of functional MR in stable patients referred for DSE for 
evaluation of ischemic heart disease is less clear. This study aimed to investigate the prevalence 
and associated implications of functional MR with long-term mortality, collectively and 
independent of other echocardiographic parameters in a large cohort of patients referred for DSE.   
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Method 
 
Study Cohort 
 
This retrospective study consisted of 6745 (3431 men and 3314 women, age 64.9±12.2 years) 
patients from a single centre with known or suspected coronary artery disease referred for DSE 
in the outpatient setting between 2005 and 2012. For patients with multiple DSE studies, only the 
first study was considered. Clinical characteristics were recorded at the time of DSE. Exclusion 
criteria included patients referred for viability assessment only and those with primary mitral 
valve disease. This investigation conformed to the Declaration of Helsinki principles. All 
patients provided informed consent before testing and the local research ethics committee 
approved the study.  
 
Transthoracic Echocardiography 
 
Before DSE, all patients underwent a full cross-sectional transthoracic echocardiogram (TTE) 
using a General Electric Vingmed System 7. All image acquisitions and measurements were 
performed as recommended by the American Society of Echocardiography.[10] LV end diastolic 
diameter, LV end systolic diameter, interventricular and LV posterior wall thickness at end 
diastole were measured from parasternal M mode recordings of the LV, with the cursor at the 
tips of the mitral valve leaflets. LV ejection fraction was determined by the modified biplane 
Simpson’s rule, with measurements averaged over three cardiac cycles. The LV endocardial 
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border was traced contiguously from one side of the mitral annulus to the other, excluding the 
papillary muscles and trabeculations.  
 
Transmitral inflow was recorded using pulsed wave Doppler recordings at the mitral valve leaflet 
tips in the apical four-chamber view. Peak velocity of early filling (E), peak velocity of atrial 
filling (A), the E/A ratio and E deceleration time were measured. Pulsed wave tissue Doppler 
imaging was performed at the septal and lateral mitral annulus in the four-chamber view, with 
results averaged in order to calculate early diastolic (E’) velocities. LV filling pressure was 
estimated from the mitral E/E’ ratio.[11]  
 
Color flow imaging was used to determine the presence or absence of MR. In all patients with 
MR, the degree of MR was graded according to semi-quantitative and quantitative methods.[12] 
MR was then graded as none/trace, mild, moderate or severe in all patients and where available 
the quantified degree of MR according to RVol and EROA as previously described.[13] Two 
accredited TTE imaging specialists retrospectively examined all TTE data in an 
echocardiography core laboratory. 
 
Dobutamine Stress Echocardiography  
 
DSE was performed according to a standard protocol [14] with dobutamine infusion starting at 
and increasing every 3-minutes with 10 gkg-1min-1 to a maximum of 40 gkg-1min-1 (stage 
4). If no end-point was reached, atropine (in doses 0.25 mg up to a maximum of 2 mg) was used. 
Mean dobutamine dose was 33.1±5 gkg-1min-1 and 1956 (29%) patients required atropine 
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(1.1±0.6 mg) to achieve target heart rate. Images of the heart were acquired in standard 
parasternal long- and short-axis and apical 2-, 3-, 4-chamber views at baseline and during 
stepwise infusion of dobutamine. Baseline, low-dose (heart rate 10-15 beats above baseline), 
peak and recovery (10-minutes post drug infusion) stage images were acquired as digital full 
cardiac cycle loops in a quad screen format and stored for off-line analysis. The LV was divided 
into a 17-segment model for qualitative analysis [15] and wall motion was scored on a 4-point 
scale (1, normal wall motion; 2, hypokinesis; 3, akinetic; and 4, dyskinetic) as is standard.[14] In 
patients with resting akinetic segments a biphasic response was used to indicate ischemia. 
Results were classified as a normal response with an overall increase in wall motion or abnormal 
response. An abnormal response was described as the occurrence under stress of hypokinesia, 
akinesia or dyskinesia in one or more resting normal segments and/or worsening of wall motion 
in one or more resting hypokinetic segments.[16] In this way patients were categorised as non-
ischemic or ischemic. The extent and location of inducible ischemia were evaluated and a wall 
motion score index (WMSI) was calculated, both at rest and during stress. Non-viable 
myocardium was defined as resting akinetic or dyskinetic LV segment without improvement 
during DSE [17] and referred to as fixed wall motion abnormalities (WMA). 
 
Follow-Up 
 
Patients were followed up from the date of their DSE test through to December 2014 and 
censored at the time of death or at last known follow-up. Mortality data were established through 
interrogation of electronic hospital or general practitioner records, contacting patients or a family 
member and through the national death registry.  
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Statistical Analysis 
 
Unless otherwise specified, data are presented as mean ± standard deviation or n (%). Group 
comparisons were performed with use of Student’s t test, analysis of variance, or 2 test, as 
appropriate. The relationship between clinical characteristics, MR severity, DSE results and all-
cause mortality was assessed using multivariable adjusted Cox regression analysis. The severity 
of MR and all-cause mortality was firstly analyzed as a categorical variable using both semi-
quantitative and quantitative techniques (n=1019) and then with the quantified degree of MR 
(n=813) using both RVol and EROA. All models were adjusted for standard cardiovascular 
disease (CVD) risk factors and included age, gender, previous history of coronary 
revascularization, myocardial infarction, and presence or absence of diabetes, family history of 
CVD, hypercholesterolaemia, hypertension, and smoking history as well as long-term cardiac 
medication (anti-anginal medication is defined as any treatment alone or in combination of beta-
blockers, calcium antagonists, or nitrates). All other variables that reached a P value <0.05 were 
entered into the final multivariate Cox model. Hazard ratios (HR) and corresponding 95% 
confidence intervals (CI) are reported.  
 
Kaplan-Meier survival curves were constructed and compared using the log-rank test and a P 
value <0.05 was used to report statistical significance. The survival curves were stratified first 
according to MR severity as a categorical variable, and second, according the presence or 
absence of MR with or without myocardial ischemia on DSE. Survival curves were then 
constructed according to the quantified degree of MR for both RVol (0 ml, 1-29 ml, and ≥30 ml) 
and EROA (0 mm2, 1-19 mm2, and ≥20 mm2). We then calculated the C statistic as a measure of 
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the incremental value of selected baseline TTE parameters (LVEF, Scar, and MR) and 
myocardial ischemia on DSE to standard CVD risk factors (basic model) and anti-anginal 
therapy. All analyses were conducted using the statistical package for social sciences (SPSS 21 
release version of SPSS for Windows; SPSS Inc., Chicago IL, USA). 
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Results 
 
Of 7042 patients referred for DSE between January 2005 and December 2012, 297 patients were 
excluded from our final analysis (104 lost at follow up, 109 referred for viability assessment only 
and 84 had primary mitral valve disease). The remaining 6745 patients are the subjects of this 
report. The patients’ mean age was 64.9±12.2 years, with 51% of the population male. The 
prevalence of hypertension, diabetes, hypercholesterolemia, family history of CVD, and prior 
history of myocardial infarction and coronary revascularization were 56, 26, 46, 25, 9, 35%, 
respectively. Seven percent of patients were current smokers.  
 
Table 1 details the baseline characteristics of the patient population according to survived and 
all-cause mortality. Of the demographic, clinical history, and long-term medication parameters; 
gender, body weight, body mass index, prevalence of hypertension, prior coronary 
revascularization, coronary revascularization during the follow-up period, smoking history, 
Canadian Cardiovascular Society (CCS) angina classification, and use of aspirin, diuretics, and 
anti-anginal therapy were significantly different between groups.   
 
Transthoracic Echocardiography 
 
As shown in Table 1, left ventricular end diastolic and end systolic diameters, LVEF, mitral 
E/E’, and the prevalence of mitral annular calcification, MR, and aortic regurgitation were 
significantly different between survived versus all-cause mortality patients. MR was present in 
1019 (15.1%) patients, with 522 (7.7%) graded mild, 371 (5.5%) graded moderate, and 126 
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(1.9%) graded severe. MR was quantitatively assessed in 813 (79.8%) of these patients, with 561 
(69%) determined by the proximal isovelocity surface area technique, 191 (23.5%) by 
quantitative Doppler and 61 (7.5%) by both techniques. In the remaining 206 (20.2%) patients, 
semi-quantitative techniques were used. When the patient population is divided into groups 
according to MR severity using semi-quantitative and quantitative techniques (Table 2); age, the 
prevalence of hypertension, diabetes, hypercholesterolemia, family history of CVD, prior 
myocardial infarction, prior coronary revascularization, smoking history, CCS angina 
classification, and beta blockade use significantly differed between groups. In addition, LVEF, 
resting and peak WMSI, fixed and new WMA significantly differed between groups based on 
MR severity (Table 2).  
 
Dobutamine Stress Echocardiography 
 
DSE was completed in all patients. 4457 (66.1%) patients had a normal DSE study, 1642 
(24.3%) patients developed a new or worsening WMA, and 1036 (15.4%) patients had fixed 
WMA. Of the patients with fixed WMA, 390 (37.6%) developed a new or worsening WMA 
during DSE. As shown in Table 1, baseline heart rate, peak diastolic blood pressure, resting and 
peak WMA, and fixed and new WMA significantly differed between survived and all-cause 
mortality patients.   
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Clinical Outcomes 
 
During a mean follow-up period of 5.1±1.8 years, all-cause mortality occurred in 1642 (24.3%) 
patients. The unadjusted Kaplan-Meier curves for the cumulative incidence of long-term all-
cause mortality, dichotomized according to A) the severity of MR as a categorical variable using 
semi-quantitative and quantitative techniques and B) MR with or without myocardial ischemia 
are presented in figure 1. The quantified degree of MR for A) RVol and B) EROA are presented 
in figure 2. The differences amongst these curves were significant (all p<0.001). The all-cause 
mortality event rate for patients with no MR was 4% per year, increasing to 8% for those with 
mild MR, 8.7% with moderate MR and peaking at 13.7% in those with severe MR. The all-cause 
mortality event rate for non-ischemic patients with no MR was 3.1% per year, increasing to 6.2% 
in non-ischemic patients with MR, 8.1% in ischemic patients with no MR and greatest at 13.8% 
in those with ischemia and MR.  
 
Following adjusted multivariate Cox regression, the demographic, clinical history, and long-term 
medication parameters that independently predicted all-cause mortality were the presence of 
hypercholesterolemia (HR 1.25; 95% CI 1.11 - 1.42; p<0.001), CCS angina classification Class 
II and Class III (HR 1.14; 95% CI 1 - 1.31 and HR 1.89; 95% CI 1.6 - 2.22; p<0.001, 
respectively) and anti-anginal therapy (HR 1.07; 95% CI 1.03 - 1.19; p=0.04). Previous 
percutaneous coronary intervention (HR 0.84; 95% CI 0.74 - 0.96; p=0.008), coronary 
revascularization during the follow-up period (HR 0.67; 95% CI 0.53 - 0.86; p=0.001) and 
treatment with lipid-lowering medication (HR 0.59; 95% CI 0.23 - 0.87; p=0.02) was associated 
with improved survival benefit. Of the TTE parameters, moderate and severe mitral regurgitation 
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were significantly associated with all-cause mortality (HR 2.78; 95% CI 2.17 - 3.57; and HR 
3.62; 95% CI 2.89 - 4.53; p<0.001, respectively), independent to parameters associated with 
adverse LV remodeling, including LV dimensions, LVEF, and resting and fixed WMA. When 
MR severity was added to the model expressed as RVol, an RVol of 1-29 ml (HR 1.99; 95% CI 
1.74 - 2.27; p<0.001) and ≥30 ml (HR 2.48; 95% CI 1.97 - 3.12; p<0.001) were independent 
predictors of all-cause mortality. In addition, when MR severity was added to the model and 
expressed as EROA, an EROA of 1-19 mm2 (HR 1.84; 95% CI 1.61 - 2.1; p<0.001) and ≥20 
mm2 (HR 6.29; 95% CI 4.96 - 7.99; p<0.001) were independent predictors of all-cause mortality.  
 
DSE parameters significantly associated with all-cause mortality were resting (HR 1.07; 95% CI 
1.02 - 1.25; p<0.001) and peak WMSI (HR 17.2; 95% CI 6.43 - 46.15; p<0.001), fixed (scar) 
WMA (HR 1.31; 95% CI 1.05 - 1.63; p=0.02), and new WMA (HR 1.32; 95% CI 1.11 - 1.74; 
p=0.004) (Table 3).  
 
The C statistic for the basic model (CVD risk factors only) was 0.55, which failed to 
significantly improve with the addition of anti-anginal therapy (0.56; p=0.73). However, there 
was a significant stepwise improvement with the addition of LVEF (0.6; p=0.002), myocardial 
ischemia on DSE (0.6; p<0.001), and MR (0.7; p=0.02), which indicates an improvement in 
discrimination (Table 4).   
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Discussion 
 
This large observational study has demonstrated that amongst patients referred for DSE, baseline 
MR is prevalent and a major determinant of all-cause mortality. This excess mortality was 
observed independently of parameters associated with LV remodeling, dobutamine induced wall 
motion abnormalities and traditional CVD risk factors. Similar to other ischemic MR studies 
[18,19,4,20,13,21,22] increasing severity of MR had a progressively negative impact on survival, 
with moderate and severe MR associated with poor outcome. The presence of moderate and 
severe MR provided incremental determination of long-term mortality when compared to 
established DSE markers of long-term adverse outcome, namely LV ejection fraction, scar 
burden, and myocardial ischemic burden. When the impact of MR severity was expressed 
quantitatively, a higher RVol and EROA are independently associated with greater all-cause 
mortality. An EROA ≥20 mm2 demonstrated a stronger association with all-cause mortality 
compared to a RVol of ≥30 ml. Nevertheless, both parameters are associated with poor outcome 
and allow further risk stratification of patients referred for DSE. This data supports previous 
research of functional MR in patients with prior myocardial infarction.[13]  
 
The AHA/ACC [23] and ESC [24] guidelines for stress echocardiography emphasize the 
importance of baseline LV ejection fraction, scar burden and presence and extent of myocardial 
ischemia as markers of adverse outcome. All of these parameters were associated with mortality 
in our patient population. The 5.1±1.8 year mortality of this patient population was 24.3% in 
keeping with previous large observational DSE studies [8,25,26] and recently in diabetic patients 
referred for stress echocardiography.[27] However, the prevalence and prognostic significance of 
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MR in a DSE population has not been specifically evaluated. MR was prevalent, being present in 
15.1% of the total population and moderate and severe MR in 7.4%. As well as being 
independently associated with all cause mortality, the presence of moderate and severe MR 
provided incremental prognostic information in our population when the C statistic model was 
constructed using standard CVD risk factors, anti-anginal therapy, LV ejection fraction, scar, 
ischemic burden and MR added in the final model. We therefore believe the presence and extent 
of MR should be clearly documented in a DSE report and should be taken into consideration 
when determining the management strategy for the patient. The timing and most appropriate 
surgical treatment option for patients with ischemic MR remains controversial, with no 
convincing evidence that surgical correction improves mortality and is therefore listed as Class 
IIb, except when the patient is undergoing coronary artery bypass graft surgery or aortic valve 
repair (Class IIa).[28-30] Current guidelines suggest patients with moderate and severe MR 
should have a multidisciplinary discussion involving an interventional cardiologist, mitral valve 
surgeon, and valve specialist.[31] In addition, correction of MR may impact other important 
outcomes, such as heart failure, which has significant financial implications for healthcare 
providers as well as patient quality of life.[32-34]  
 
Anti-anginal therapy in patients referred for stress echocardiography has been shown to 
adversely affect outcome.[27,35] In our study, anti-anginal therapy was independently associated 
with all-cause mortality and a greater proportion of patients with severe MR were prescribed 
beta-blockers.  
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MR can be a dynamic lesion and as such its severity may change over time and under stress 
conditions. Evaluation of MR under exercise provides prognostic information over resting 
measures and identifies high-risk patients with poor outcome.[36,37] However, DSE often 
improves MR [38] and patients referred are usually unable to exercise or have poor exercise 
capacity. This study however, has demonstrated that qualitative and quantitative baseline MR has 
a significant impact on all-cause mortality and should be considered in conjunction with DSE 
results. 
 
Study Limitations 
 
This is a single centre observational study and may be limited by potential referral, selection, 
ascertainment, and reporting biases and limited generalizability. Functional MR is a 
heterogeneous disease and in this study the different categories were not determined. In addition, 
measurements associated with MR severity are complex and subject to limitations.[39] However, 
quantitative techniques have been shown to be accurate and reproducible in single centers.[40] 
Furthermore, the dynamic nature of MR was not assessed during dobutamine infusion. However, 
as detailed previously, MR usually improves with dobutamine stress and the authors believe 
dynamic changes are better investigated using dynamic exercise. 
 
Conclusions 
 
Baseline MR was independently associated with greater mortality. As such, it could be suggested 
that qualitative and quantitative interrogation of valvular function be routinely evaluated and 
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reported in patients referred for DSE. The rate of all-cause mortality increased with worsening 
MR and was exacerbated with the addition of myocardial ischemia. In lower-risk patients 
optimal medical management and careful follow-up with repeated assessment of MR should be 
performed.     
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Figure Legends 
 
Figure 1: Kaplan-Meier curve for the cumulative survival and freedom from long-term mortality 
dichotomized according to the degree of mitral regurgitation as a categorical variable (A) and 
according to the presence or absence of mitral regurgitation with or without myocardial ischemia 
during dobutamine stress echocardiography (B). 
 
Figure 2: Kaplan-Meier curve for the cumulative survival and freedom from long-term mortality 
dichotomized according to the quantified severity of mitral regurgitation using regurgitant 
volume (A) and effective regurgitant orifice area (B). 
